RV-PA Coupling Index (ECHO-based) Calculator

Clinical calculation support · Verify results before clinical use

Echocardiographic measurements

Enter TAPSE and systolic pulmonary artery pressure to calculate the primary ratio. Additional indices are optional.

—mm/mmHg
Tricuspid annular plane systolic excursion, measured by M-mode in mm.
Estimated systolic pulmonary artery pressure in mmHg. The estimate depends on TR velocity and right atrial pressure assumptions.
Enter as a percentage, for example 35.
Enter the absolute magnitude of strain, not the negative signed value.

Clinical interpretation

Right ventricular–pulmonary artery (RV–PA) coupling describes how RV systolic performance adapts to pulmonary arterial load. Invasive assessment commonly relates end-systolic elastance to arterial elastance (Ees/Ea); echocardiographic indices such as TAPSE/PASP are practical surrogates rather than direct measurements of Ees/Ea.

Primary index: TAPSE/PASP

The ratio is calculated as TAPSE (mm) divided by estimated PASP/sPAP (mmHg). Lower values indicate less longitudinal RV excursion relative to estimated systolic pressure. ESC/ERS pulmonary hypertension guidance lists TAPSE/sPAP <0.55 mm/mmHg as an additional echocardiographic sign; a cut-off near 0.31 has been studied for uncoupling in severe pulmonary hypertension, while ≤0.32 has been used to identify severe uncoupling in selected structural-intervention cohorts. These thresholds are not interchangeable universal diagnostic categories.

Optional complementary indices

  • RV FAC/PASP: a 0.71 %/mmHg prognostic cut-off was reported in the COAPT secondary mitral regurgitation population. It should not be generalized uncritically to all patients.
  • RVFWLS/PASP: a 0.46 %/mmHg cut-off was reported in a small 2025 HFrEF and ventricular secondary mitral regurgitation cohort. This is preliminary, population-specific evidence.
  • TAPSE/mPAP: sex-specific prognostic thresholds were reported in a transcatheter tricuspid valve intervention cohort; they are not universal reference ranges.

Practical limitations

TAPSE is angle- and load-dependent and reflects longitudinal motion rather than global RV function. PASP estimates may be unreliable with an inadequate TR Doppler envelope, severe tricuspid regurgitation, or uncertain right atrial pressure. Interpret alongside RV FAC, S′, RV strain, RV size, RA/IVC findings, TR severity, clinical status, and invasive hemodynamics when indicated.

Evidence and references

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43:3618–3731. Includes TAPSE/sPAP <0.55 mm/mmHg among additional echocardiographic signs suggestive of PH. Official DOI.
Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Primary study; reports a TAPSE/PASP cut-off of 0.31 mm/mmHg in severe PH. PubMed record.
Right Ventricular–Pulmonary Arterial Coupling in Patients With HF Secondary MR: Analysis From the COAPT Trial. JACC: Cardiovascular Interventions. 2021. Reports a cohort-specific FAC/PASP cut-off of 0.71 %/mmHg. Journal article.
Hădăreanu CD, et al. Prognostic value of the ratio between right ventricular free wall longitudinal strain and systolic pulmonary artery pressure in patients with HFrEF and ventricular secondary mitral regurgitation. Frontiers in Cardiovascular Medicine. 2025. DOI: 10.3389/fcvm.2025.1611772. Full article.
Sex-Related Differences in Clinical Characteristics and Outcome Prediction Among Patients Undergoing Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions. 2023. Reports sex-specific TAPSE/mPAP prognostic cut-offs in this population. Journal article.
Clinical disclaimer: This calculator provides arithmetic and evidence-informed contextualization, not a definitive diagnosis or individualized treatment recommendation. Thresholds vary by disease, population, measurement technique, and endpoint. Do not use the output as the sole basis for clinical decisions.